InDex Pharmaceuticals AB
Yesterday, InDex and Flerie hosted an investor meeting regarding the proposed reverse merger that was announced on May 20. You can watch a recording of the presentations through the link below.
www.redeye.se © All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2024
New patent for granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease with an exclusivity period until August 2040.
Read more: https://lnkd.in/eyM2EbDr
“We are pleased to announce that the final patient visit needed for the dose selection analysis has occurred. We have seen great progress in the study and an accelerated patient recruitment rate since January this year. We are very grateful to the patients, investigators and study personnel for their time and commitment. We will present the outcome of the dose selection analysis in Q4 this year, as previously communicated.”
Jenny Sundqvist, CEO
Press release: https://www.indexpharma.com/en/index-pharmaceuticals-announces-that-all-patients-needed-for-the-cobitolimod-dose-selection-milestone-have-completed-induction-study-1-of-the-phase-iii-program-conclude/
Klicka här för att få din sponsrade notering.
Webbplats
Adress
Berzelius Väg 13
Stockholm
17165
